Lymphoplasmacytic lymphoma classification: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Line 4: Line 4:
{{CMG}}; {{AE}}{{S.M.}}
{{CMG}}; {{AE}}{{S.M.}}
==Overview==
==Overview==
There is no established system for the classification of lymphoplasmacytic lymphoma. However, according to a devised criteria based upon patient's symptoms, Waldenström's macroglobulinemia can be further classified into smoldering/asymptomatic and symptomatic WM .
There is no established system for the classification of lymphoplasmacytic lymphoma. However, according to a devised criteria based upon patient's symptoms, [[Waldenström's macroglobulinemia]] can be further classified into smoldering/asymptomatic and symptomatic WM .


==Classification==
==Classification==
There is no established system for the classification of lymphoplasmacytic lymphoma. However, according to a devised criteria based upon patient's symptoms, Waldenström's macroglobulinemia can be further classified into:<ref name="pmid15735132">{{cite journal| author=Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP| title=Diagnosis and management of Waldenstrom's macroglobulinemia. | journal=J Clin Oncol | year= 2005 | volume= 23 | issue= 7 | pages= 1564-77 | pmid=15735132 | doi=10.1200/JCO.2005.03.144 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15735132  }} </ref>
There is no established system for the classification of lymphoplasmacytic lymphoma. However, according to a devised criteria based upon patient's symptoms, [[Waldenström's macroglobulinemia]] can be further classified into:<ref name="pmid15735132">{{cite journal| author=Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP| title=Diagnosis and management of Waldenstrom's macroglobulinemia. | journal=J Clin Oncol | year= 2005 | volume= 23 | issue= 7 | pages= 1564-77 | pmid=15735132 | doi=10.1200/JCO.2005.03.144 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15735132  }} </ref>
*Symptomatic Waldenstrom macroglobulinemia.
*Symptomatic [[Waldenstrom macroglobulinemia]].
*Asymptomatic/Smoldering Waldenstrom macroglobulinemia (SWM).<ref name="pmid12720119">{{cite journal| author=Kyle RA, Treon SP, Alexanian R, Barlogie B, Björkholm M, Dhodapkar M et al.| title=Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. | journal=Semin Oncol | year= 2003 | volume= 30 | issue= 2 | pages= 116-20 | pmid=12720119 | doi=10.1053/sonc.2003.50038 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12720119  }} </ref>
*Asymptomatic/Smoldering [[Waldenstrom macroglobulinemia]] (SWM).<ref name="pmid12720119">{{cite journal| author=Kyle RA, Treon SP, Alexanian R, Barlogie B, Björkholm M, Dhodapkar M et al.| title=Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. | journal=Semin Oncol | year= 2003 | volume= 30 | issue= 2 | pages= 116-20 | pmid=12720119 | doi=10.1053/sonc.2003.50038 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12720119  }} </ref>
{| class="wikitable"
{| class="wikitable"
|+ '''Classification of WM and Related Disorders'''
|+ '''Classification of WM and Related Disorders'''
Line 19: Line 19:
|-
|-
| style="background:#DCDCDC;" align="center" + |IgM monoclonal protein
| style="background:#DCDCDC;" align="center" + |IgM monoclonal protein
| style="background:#F5F5F5;" align="center" + |+
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + |+
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + |+
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + |+
| style="background:#F5F5F5;" align="center" + | +
|-
|-
| style="background:#DCDCDC;" align="center" + |Bone marrow infiltration
| style="background:#DCDCDC;" align="center" + |Bone marrow infiltration
| style="background:#F5F5F5;" align="center" + |+
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + |+
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + |-
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + |-
| style="background:#F5F5F5;" align="center" + | -
|-
|-
| style="background:#DCDCDC;" align="center" + |Symptoms attributable to IgM
| style="background:#DCDCDC;" align="center" + |Symptoms attributable to IgM
| style="background:#F5F5F5;" align="center" + |+
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + |-
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + |+
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + |-
| style="background:#F5F5F5;" align="center" + | -
|-
|-
| style="background:#DCDCDC;" align="center" + |Symptoms attributable to tumor infiltration
| style="background:#DCDCDC;" align="center" + |Symptoms attributable to tumor infiltration
| style="background:#F5F5F5;" align="center" + |+
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + |-
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + |-
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + |-
| style="background:#F5F5F5;" align="center" + | -
|}
|}


Revision as of 21:12, 18 February 2019

Lymphoplasmacytic lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Lymphoplasmacytic Lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Lymphoplasmacytic lymphoma classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Lymphoplasmacytic lymphoma classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Lymphoplasmacytic lymphoma classification

CDC on Lymphoplasmacytic lymphoma classification

Lymphoplasmacytic lymphoma classification in the news

Blogs on Lymphoplasmacytic lymphoma classification

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Lymphoplasmacytic lymphoma classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]

Overview

There is no established system for the classification of lymphoplasmacytic lymphoma. However, according to a devised criteria based upon patient's symptoms, Waldenström's macroglobulinemia can be further classified into smoldering/asymptomatic and symptomatic WM .

Classification

There is no established system for the classification of lymphoplasmacytic lymphoma. However, according to a devised criteria based upon patient's symptoms, Waldenström's macroglobulinemia can be further classified into:[1]

Classification of WM and Related Disorders
Criteria Symptomatic WM Asymptomatic WM IgM-Related Disorders MGUS
IgM monoclonal protein + + + +
Bone marrow infiltration + + - -
Symptoms attributable to IgM + - + -
Symptoms attributable to tumor infiltration + - - -

References

  1. ↑ Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP (2005). "Diagnosis and management of Waldenstrom's macroglobulinemia". J Clin Oncol. 23 (7): 1564–77. doi:10.1200/JCO.2005.03.144. PMID 15735132.
  2. ↑ Kyle RA, Treon SP, Alexanian R, Barlogie B, Björkholm M, Dhodapkar M; et al. (2003). "Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia". Semin Oncol. 30 (2): 116–20. doi:10.1053/sonc.2003.50038. PMID 12720119.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Lymphoplasmacytic_lymphoma_classification&oldid=1551511"